

Excelra releases COVID-19 biomarker database

12 June 2020 | News

This resource is excerpted from Excelra's GOBIOM platform

Hyderabad based Excelra, a leading global data-analytics company has announced the release of the COVID-19 Biomarker Database (<https://www.excelra.com/covid-19-biomarker-database/>) in support of the ongoing global scientific efforts, aimed at developing safe and effective therapeutic options to treat the novel coronavirus disease.

This resource is excerpted from Excelra's GOBIOM platform - the world's largest biomarker intelligence database. With reference to this endeavour, Dr. Raveendra Dayam, Director, Chemistry and Biology Data Services, Excelra, said, "The COVID-19 Biomarker Database is a compilation of manually curated biomarkers from published clinical trials, evaluating potential drugs or biologics for the treatment of SARS-CoV-2. The database additionally includes information on FDA-NIH recommended BEST (Biomarkers, Endpoints and other Tools) classification of biomarkers, supported with referenced literature."

The information in the COVID-19 Biomarker Database is presented in a user-friendly online application and the data is regularly updated with new biomarkers from clinical trials published in clinicaltrials.gov.

Excelra's GOBIOM is the world's largest manually curated database of validated and putative biomarkers, providing a comprehensive overview of the biomarker-disease relationship. Integrated with information encompassing the exploratory, preclinical and clinical domains, the database provides critical insights into diagnosis, prognosis, treatment response, safety, efficacy and toxicity. As a one-stop source for biomarker intelligence, GOBIOM enables informed clinical and therapeutic decision making to accelerate drug development.